Fundraising Fox

Allogene

NASDAQ: ALLO

Delaware corporation · 4 known investors

allogene.com ↗

Allogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches. The company aims to expand CAR T treatment access through scalable manufacturing, lower costs, and faster treatment delivery.

BiotechHealthtechMedical Devicesin /allogene-therapeutics@AllogeneTx

Founders & leadership

RA
ROBERT ABRAHAMDirector
OW
OWEN WITTEDirector
DB
DAVID BONDERMANDirector
TS
TODD SISITSKYDirector
JA
JOSHUA A. KAZAMExecutive Officer, Director
DM
DAVID M. TANENExecutive Officer
DC
DAVID CHANGDirector
FH
FRANZ HUMERDirector
AB
ARIE BELLDEGRUNDirector
JD
JOHN DEYOUNGDirector

Investors · 4

Avoro Capital AdvisorsNew York
Foresite CapitalLarkspur
TPGSan Francisco
Vida VenturesLos Angeles

Reported raises · per SEC filings

Form D private placements
▶$411.8MraisedApr 2018 · 23 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • ROBERT ABRAHAMDirector
  • OWEN WITTEDirector
  • DAVID BONDERMANDirector
  • TODD SISITSKYDirector
  • JOSHUA A. KAZAMExecutive Officer, Director
  • DAVID M. TANENExecutive Officer
  • DAVID CHANGDirector
  • FRANZ HUMERDirector
  • ARIE BELLDEGRUNDirector
  • JOHN DEYOUNGDirector
Offering amount
$411.8M
Amount sold
$411.8M
First sale
Apr 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news